key: cord-1019217-bn93f9dd
authors: Traish, Abdulmaged M.
title: Sex Steroids and COVID-19 Mortality in Women
date: 2021-04-19
journal: Trends Endocrinol Metab
DOI: 10.1016/j.tem.2021.04.006
sha: 28884e148f024f582b1c3bd3e9da421a64159952
doc_id: 1019217
cord_uid: bn93f9dd

More men died of COVID-19 than women, suggesting estrogens may protect women. However, COVID-19 deaths among men and women were inconsistent among countries throughout the world. Genetics, epigenetics and inborn errors of immunity may account for the disparity in mortality among men and women with COVID-19 than sex steroid hormones.

Sex steroid hormones were implicated in the outcomes of COVID-19 infection, disease severity and mortality in men and women, albeit without credible biochemical or physiological evidence. Pinna [1] suggested that "evidence shows coronavirus disease 2019 (COVID-19)induced symptom severity and mortality is more frequent in men than in women, suggesting estrogens and progestins may play a protective role in women but not in men." Yet, no credible biochemical, physiological or clinical evidence were provided to support such a broad and fundamentally important scientific supposition [1] . It is worth emphasizing that men do synthesize and secrete estrogens, albeit at reduced concentrations compared to women, which would be expected to confer similar physiological action in men [2] . Similarly, men produce progesterone in significant amounts [3] . Thus, the hypothesis that gender disparity in COVID-19 infection and disease severity is attributed, mainly, to estrogens and progesterone is, at best, simplistic and profoundly unsubstantiated [1] . If the advanced hypothesis that "Estradiol and progesterone are potent immune-modulators and confer protective advantages in women compared to men against COVID-19 disease severity and outcomes is correct", then the following predictions should be confirmed. To date, the exact underlying pathophysiological mechanisms contributing to COVID-19 susceptibility to infection, increased disease presentation and severity and increased mortality in men and women remains incompletely understood. Nevertheless, viral and host genetic variants are likely key factors impacting the immune response, disease severity and mortality.

Surprisingly, clinical trials on use of estrogens in men and women were commenced to determine their effectiveness against COVID19, without biochemical or physiological data to establish a proof of concept or proof of relevance [1, 5] . Use of estrogens as therapeutic modalities against COVID19 has been proposed, even in the absence of clinical trials. In our view, such propositions are, at best, premature. Furthermore, there is no credible evidence to suggest that sex hormones per se are responsible for the disparity in COVID19 infections, disease severity and death among men and women.

Moreover, considerable clinical variability was encountered among individuals infected with COVID19 ranging from asymptomatic, mild to moderate diseases to severe and lifethreatening disease that results in mortality [6] [7] [8] . Type-I IFNs are thought to be essential for sustained antiviral immunity, and type-I IFNs deficiency is a hallmark of severe COVID-19 [9] . IFN activity in serum of patients with severe or critical COVID19 disease was significantly reduced compared to those with mild to moderate COVID19 disease severity [9] . Thus, it is plausible that COVID19 disease severity is associated with markedly impaired interferon (IFN) type I response with no IFN- and low IFN- production and activity. Patients with impaired type I IFN response in severe and critical COVID-19 patients exhibited high blood viral load and an excessive NF-kB-driven inflammatory response associated with increased TNF- and IL-6 [9] . Thus, the role of genetics and inborn errors of immunity may contribute to greater COVID19-related mortality among men compared to women rather than circulating sex steroid hormone levels [6] [7] [8] [9] [10] .

Bastard et al., [7] proposed that inborn errors of cytokine immunity may, in part, contribute to the observed disparity in disease severity among individuals, and in particular among men and women. It was suggested that inborn errors of type-I IFNs and neutralizing autoantibodies (auto-Abs) against type-I IFNs possibly underlie the greater variability of severe adverse respiratory disease. For example, neutralizing immunoglobulin G (IgG) autoantibodies J o u r n a l P r e -p r o o f Journal Pre-proof (auto-Abs) against interferon- (IFN-) and IFN- were detected in patients with onset of critical COVID19 disease. However, no auto-Abs were detected in individuals with asymptomatic or mild COVID19 infections. The excess of auto-Abs was greater in men with critical COVID-19 pneumonia and neutralizing auto-Abs against type-I IFNs and was equally higher than that observed in patients with critical COVID-19 without auto-Abs men with asymptomatic disease. Interestingly, inborn errors of type-I IFN immunity, which accounts for life-threatening COVID-19 pneumonia was detected in at least 2.6% of women and 12.5% of men. This observation suggests that more men exhibited inborn errors of immunity than women.

These findings provide an alternative explanation for the major sex bias seen in patients with life-threatening COVID-19 among men women.

Zhang et al., [6] reported that at least 3.5% of patients with life threatening COVID-19 pneumonia had known autosomal-recessive (AR) interferon regulatory factor 7 (IRF7) and IFNAR1 deficiencies or autosomal dominant (AD) Toll-like receptor 3 (TLR3), TICAM1, TBK1, and IRF3 deficiencies or new (AD UNC93B1, IRF7, IFNAR1, and IFNAR2 deficiencies.

In patients with life-threatening COVID19, there was a higher proportion of men with inborn errors of type 1IFN immunity than women at all ages [ Figure 1 panel A] . This, however, was not the case in the asymptomatic patients [6, 7] . Takahashi and Iwasaki [10] proposed a potential mechanism that may explain the sex differences pertaining to biochemical factors that modulate infection and immunity in COVID-19 in men and women [ Figure 1 Panel B] and further suggested that each of these steps may shape the antiviral immune response in men and women.

It is important to marshal sound scientific evidence based on biochemical and physiological data in order to propose clinical trials or advocate for the use of sex steroid hormones in COVID19 patients. The sex disparity of COVID-19 related morbidity and mortality is likely explained by a combination of biological sex differences, such as inborn errors of immunity and gender-specific factors. Griffith et al., [11] noted that the mechanisms underlying sex differences in mortality remain unknown and a combination of biological, behavioral, and psychosocial factors may account for individuals' health patterns. Krieger et al., 2020 [12], raised skepticism regarding the notion that increased deaths in men are entirely due to sex or gender.

In summary, none of the predictions set forth related to sex steroid hormones and disparity of COVID19 disease severity and mortality among men and women could be confirmed. We suggest that inborn errors of immunity and genetics appear to be more critical in life-threatening COVID19 than circulating sex steroid hormones. Advocating for use of estrogens and progesterone to treat COVID19 patients is not supported by biochemical, physiological or clinical credible evidence. Caution should be exercised regarding the claims that sex steroid hormones account for the gender disparity in COVID-19 infection severity and mortality. J o u r n a l P r e -p r o o f

Sex and COVID-19: A Protective Role for Reproductive Steroids

Mechanisms in Endocrinology: Estradiol as a male hormone

Progesterone: the forgotten hormone in men?

Evidence for treatment with estradiol for women with SARS-CoV-2 infection

Inborn errors of type I IFN immunity in patients with life-threateningCOVID-19

Autoantibodies against type I IFNs in patients with lifethreatening COVID-19

Is susceptibility to severe COVID-19 disease an inborn error of metabolism?

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Sex differences in immune responses

Men and COVID-19: A biopsychosocial approach to understanding sex differences in mortality and recommendations for practice and policy interventions